ZEPU-AI1 Gait Robot Training Study (ZEPUAI1RCT)
NCT07735676
Brain Diseases, Cardiovascular Diseases
Dhaka, Bangladesh
View Trial DetailsNCT Number: NCT07544927
This study aims to validate the clinical performance of an artificial intelligence (AI)-based automatic scoring system for the Modified Rankin Scale (mRS). The core comparison is the consistency and accuracy between the AI-generated scores and standardized manual mRS follow-up assessments performed by trained professionals. The goal is to provide a convenient, efficient, and objective tool for stroke prognosis assessment, reduce the subjective variability of manual scoring, and optimize the stroke follow-up workflow.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
This is a prospective, multicenter, observational study designed to validate the diagnostic performance of an AI-based automated scoring system for the Modified Rankin Scale (mRS) in patients with stroke. The primary objective is to evaluate the agreement between AI-generated mRS scores and standardized manual assessments conducted by trained clinicians. Secondary endpoints include the system's sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) in classifying functional outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7 days post-discharge or post-outpatient visit, ± 2 days
The weighted kappa coefficient quantifies the level of agreement between the Artificial Intelligence (AI)-generated Modified Rankin Scale (mRS) scores and the standardized manual mRS assessments performed by trained clinicians
Time frame: 7 days post-discharge or post-outpatient visit, ± 2 days
The simple kappa coefficient quantifies the level of agreement between the Artificial Intelligence (AI)-generated dichotomized Modified Rankin Scale (mRS) scores (0-2 vs. 3-6) and the standardized manual mRS assessments performed by trained clinicians
Time frame: 7 days post-discharge or post-outpatient visit, ± 2 days
The Bland-Altman limits of agreement analysis evaluates the consistency between the Artificial Intelligence (AI)-generated and manually assessed Modified Rankin Scale (mRS) scores. The difference between manual and AI scores will be plotted on the y-axis against their mean on the x-axis, with limits of agreement (mean difference ± 1.96 × standard deviation) calculated. The analysis aims to visually assess how agreement varies across the range of mRS scores and identify any proportional bias, such as greater disagreement in patients with severe disability.
Time frame: 7 days post-discharge or post-outpatient visit, ± 2 days
The diagnostic performance analysis evaluates the ability of the Artificial Intelligence (AI)-based Modified Rankin Scale (mRS) scoring system to classify functional outcomes, using manual assessment as the reference standard. A 2×2 contingency table will be constructed for the dichotomized mRS categories (good outcome: 0-2 vs. poor outcome: 3-6). The analysis will calculate sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and Youden's index. A receiver operating characteristic (ROC) curve will be plotted, and the area under the curve (AUC) will be computed.
Contact information is provided by the study sponsor or research team.
Qingfeng Ma, MD
CONTACT
Zixin Wang, MD Candidate
CONTACT
Xuanwu Hospital, Beijing
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735676
Brain Diseases, Cardiovascular Diseases
Dhaka, Bangladesh
View Trial DetailsNCT07735702
Brain Diseases, Cardiovascular Diseases
Dhaka, Bangladesh
View Trial DetailsNCT07740668
Brain Diseases, Cardiovascular Diseases
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT07739264
Brain Diseases, Brain Injuries
Dhaka, Bangladesh
View Trial Details